Enhertu Injection, Powder, Lyophilized, For Solution
Product Images NDC 65597-406

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Enhertu (NDC 65597-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Daiichi Sankyo Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Enhertu 01)

Chemical Structure (Enhertu 01)
The text seems to be a list of terms, specifically describing a drug called Deruxtecan. It is a topoisomerase I inhibitor, and it appears to have a certain concentration of 8 molecules of Deruxtecan per mAb (however, it is unclear what "mAb" stands for). A linker may also be involved in the drug's composition.*
FDA Label Image

Figure 1 (Enhertu 02)

Figure 1 (Enhertu 02)
This appears to be a graph or table with numerical values plotted on two axes. The horizontal axis represents time (in months) and the vertical axis shows a progression-free survival rate (%) for two different treatments: ENHERTU and Ado-trastuzumab emtansine. Each line on the graph corresponds to a different time point (0-32 months) and shows the percentage of patients who have not progressed on each treatment at that time point. There are also numbers at risk listed for each time point, indicating the number of patients still receiving the treatment and being monitored for progression-free survival.*
FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Principal Display Panel (100 mg Vial Carton)
FDA Label Image

Enhertu 04

Enhertu 04
ENHERTU is a medication sold in single-dose vials for intravenous infusion only. It is used in the treatment of cancer and contains fam-trastuzumab deruxtecan-nxki (100mg per vial). The medication guide is enclosed and must be dispensed to each patient. Reconstitution and dilution are necessary before administration, and unused portions should be discarded. ENHERTU is hazardous and must be stored refrigerated between 36°F to 46°F. The reconstituted solution should also be kept refrigerated up to 24 hours after reconstitution and protected from light. Each vial contains fam-trastuzumab denuxtecan-ncki, L-histidine, listdine hydrochloride monohydrate, polysorbate 80, and sucrose. Daiichi Sankyo Company produces ENHERTU in Japan. ENHERTU is a registered trademark of Daiichi Sankyo Company.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.